About Gendicine

About Gendicine

Gendicine was the first gene drug to be approved for marketing in humans, and it was marketed in 2004. Jin Yousheng is so far the world's only successful large-scale production of gene drugs, its holder is Shenzhen SiBiono Gene Technology Co., LTD. SiBiono exclusively entrusted the custom production of Gendicine to the Scinosen gene drug CDMO platform and exclusively licensed its key patents related to adenovirus vectors to Scinosen. The Scinosen gene drug CDMO platform for Gendicine has a capacity of up to 1 million doses per year (1.0×10¹² VP/vial).

The successful development of Gendicine is a milestone achievement in the field of human genes, and its listing has opened a new era of human gene therapy, and also made China walk in the forefront of the world in the field of gene medicine. In October 2006, Gendicine was featured on the cover of Time in the United States, reporting on the successful large-scale clinical application of Gendicine and tumor gene therapy in China under the title "Asian's Science Revolution". This is the glory of the Chinese in the field of genetics and the glory of the entire team behind Gendicine, which has now all joined Scinosen.

Gendicine is by far the most widely used gene drug in the world, and the only gene drug that has successfully achieved mass production. Since its approval, Gendicine has served the world's largest group of patients who have received gene therapy and accumulated valuable and potentially valuable gene therapy clinical big data.